Study of Efgartigimod to Reduce Corticosteroid Use in Elderly Patients with Generalized Anti-AChR Myasthenia Gravis Using IV or SC Treatment

What this Trial Is About

Generalized Myasthenia Gravis gMG is a rare autoimmune disorder that causes muscle weakness and fatigue due to antibodies that affect nerve-muscle connections. This condition mainly affects elderly patients who often face persistent symptoms and side effects from treatments like corticosteroids, which can increase risks such as infections, heart problems, and other chronic diseases. Researchers are evaluating efgartigimod, a new drug that targets harmful antibodies, to see if it can help reduce corticosteroid use and improve symptoms and quality of life in elderly gMG patients. Participants in this study will receive efgartigimod either through intravenous IV infusion or subcutaneous SC injection. This observational study will monitor patients who are already using high or intermediate doses of corticosteroids and have developed related health issues. The study aims to assess how efgartigimod affects corticosteroid dosage and patient health over a 12-month period. During the study, participants will attend scheduled visits for assessments including physical exams, laboratory tests, and monitoring of corticosteroid doses and side effects. Researchers will measure changes in corticosteroid use, muscle strength, comorbidities, and overall health. The study will also track quality of life and safety outcomes. Participation will last at least 12 months, with evaluations focusing on corticosteroid dose reduction and health improvements.

Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod